Tango details Phase 3 plans for pancreatic cancer combo, holds $977.5 millionNov 16Regulatory decisionKura Oncology, Inc.Summit TherapeuticsUpdated
Kura Oncology registers rBA/bioequivalence study of ziftomenib in R/R AML and MDSNov 10Trial updateKura Oncology, Inc.ziftomenib
Kura Oncology spins out Caspian Therapeutics for cardiometabolic menin inhibitorsSep 9FinancingKura Oncology, Inc.
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Kura Oncology updates severance terms for CEO and two other executivesJul 29PeopleKura Oncology, Inc.